Rheumatoid Arthritis (RA)

Immunology
24
Pipeline Programs
15
Companies
22
Clinical Trials
4 recruiting
5
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
6
1
6
9
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 19 programs with unclassified modality

On Market (5)

Approved therapies currently available

U
JYLAMVOApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]oral2022
Bristol Myers Squibb
ORENCIAApproved
abatacept
Bristol Myers Squibb
Selective T Cell Costimulation Modulator [EPC]iv (infusion)2005
U
OTREXUPApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]subcutaneous2013
U
OTREXUP PFSApproved
methotrexate
Unknown Company
Folate Analog Metabolic Inhibitor [EPC]subcutaneous2013
Astellas
PROGRAFApproved
tacrolimus
Astellas
oral1994

Competitive Landscape

15 companies ranked by most advanced pipeline stage

Bristol Myers Squibb
4 programs
3
1
TNF AntagonistPhase 41 trial
SubcutaneousPhase 34 trials
SubcutaneousPhase 31 trial
abataceptPhase 31 trial
Active Trials
NCT05337345Completed104Est. Dec 2022
NCT02722694Unknown360Est. Dec 2017
NCT02366871Completed400Est. Jun 2019
+4 more trials
E
EisaiChina - Liaoning
1 program
1
MethotrexatePhase 41 trial
Active Trials
NCT06913907Recruiting100Est. Dec 2027
Genentech
GenentechCA - Oceanside
1 program
1
TNF AntagonistPhase 4
Astellas
AstellasChina - Shenyang
1 program
1
tacrolimusPhase 41 trial
Active Trials
NCT03737708Completed21Est. Jun 2020
AbbVie
AbbVieNORTH CHICAGO, IL
2 programs
1
1
AbataceptPhase 31 trial
ABBV-154Phase 21 trial
Active Trials
NCT04888585Terminated473Est. Aug 2023
NCT03086343Completed657Est. Jun 2023
mAbxience
mAbxienceSwitzerland - Lugano
1 program
1
MB04Phase 31 trial
Active Trials
NCT06596772Recruiting458Est. Jan 2026
CP
Chugai PharmaJapan - Tokyo
1 program
1
Tocilizumab + methotrexatePhase 31 trial
Active Trials
NCT01258712Completed86Est. Oct 2012
AS
AB ScienceFrance - Paris
1 program
1
masitinib 3 mgPhase 2/31 trial
Active Trials
NCT01410695TerminatedEst. Oct 2015
Antares Therapeutics
2 programs
2
MTXPhase 21 trial
VIBEX MTXPhase 21 trial
Active Trials
NCT01618968CompletedEst. Aug 2012
NCT01618955CompletedEst. Jul 2012
SynAct Pharma
SynAct PharmaSweden - Lund
1 program
1
AP1189, 40 mgPhase 21 trial
Active Trials
NCT06671054Recruiting240Est. Dec 2025
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
1
Moderna mRNA-1273Phase 2RNA Therapeutic1 trial
Active Trials
NCT05000216TerminatedEst. Mar 2024
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
QLS12010Phase 21 trial
Active Trials
NCT07377773Not Yet RecruitingEst. Jun 2028
Philogen
PhilogenItaly - Monteriggioni
1 program
1
F8IL10Phase 11 trial
Active Trials
NCT07245992Recruiting42Est. Sep 2029
H
HutchmedChina - Hong Kong
1 program
1
HMPL-523Phase 11 trial
Active Trials
NCT02105129Completed118Est. Dec 2015
UP
UCB PharmaBelgium - Brussels
1 program
UCB Cimzia Pregnancy Follow-up StudyN/A1 trial
Active Trials
NCT02775656Terminated1Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
EisaiMethotrexate
Astellastacrolimus
Bristol Myers SquibbTNF Antagonist
mAbxienceMB04
AbbVieAbatacept
Bristol Myers SquibbSubcutaneous
Chugai PharmaTocilizumab + methotrexate
Bristol Myers SquibbSubcutaneous
Bristol Myers Squibbabatacept
AB Sciencemasitinib 3 mg
Qilu PharmaceuticalQLS12010
SynAct PharmaAP1189, 40 mg
Allergy TherapeuticsModerna mRNA-1273
AbbVieABBV-154
Bristol Myers SquibbSubcutaneous

Showing 15 of 22 trials with date data

Clinical Trials (22)

Total enrollment: 6,186 patients across 22 trials

NCT06913907EisaiMethotrexate

Changes in MTX-PG Concentrations During Subcutaneous MTX Therapy in Patients With Rheumatoid Arthritis(COSMOS Study)

Start: Apr 2025Est. completion: Dec 2027100 patients
Phase 4Recruiting
NCT03737708Astellastacrolimus

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Start: Feb 2019Est. completion: Jun 202021 patients
Phase 4Completed
NCT02353780Bristol Myers SquibbTNF Antagonist

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Start: Mar 2015Est. completion: Nov 201810 patients
Phase 4Terminated
NCT06596772mAbxienceMB04

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Start: Oct 2024Est. completion: Jan 2026458 patients
Phase 3Recruiting
NCT03086343AbbVieAbatacept

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Start: May 2017Est. completion: Jun 2023657 patients
Phase 3Completed
NCT02722694Bristol Myers SquibbSubcutaneous

A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Start: Aug 2016Est. completion: Dec 2017360 patients
Phase 3Unknown
NCT01258712Chugai PharmaTocilizumab + methotrexate

Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients

Start: Dec 2010Est. completion: Oct 201286 patients
Phase 3Completed
NCT00559585Bristol Myers SquibbSubcutaneous

Methotrexate-Inadequate Response Study

Start: Jan 2008Est. completion: Sep 20142,492 patients
Phase 3Completed
NCT00547521Bristol Myers Squibbabatacept

Phase IIIB Subcutaneous Abatacept Monotherapy Study

Start: Dec 2007Est. completion: Feb 2014119 patients
Phase 3Completed
NCT01410695AB Sciencemasitinib 3 mg

Masitinib in Refractory Active Rheumatoid Arthritis

Start: Jul 2011Est. completion: Oct 2015
Phase 2/3Terminated
NCT07377773Qilu PharmaceuticalQLS12010

QLS12010 in Participants With Moderate-to-severe Rheumatoid Arthritis

Start: Mar 2026Est. completion: Jun 2028
Phase 2Not Yet Recruiting
NCT06671054SynAct PharmaAP1189, 40 mg

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

Start: Oct 2024Est. completion: Dec 2025240 patients
Phase 2Recruiting
NCT05000216Allergy TherapeuticsModerna mRNA-1273

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Start: Aug 2021Est. completion: Mar 2024
Phase 2Terminated
NCT04888585AbbVieABBV-154

Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Start: Jun 2021Est. completion: Aug 2023473 patients
Phase 2Terminated
NCT02366871Bristol Myers SquibbSubcutaneous

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Start: Apr 2015Est. completion: Jun 2019400 patients
Phase 2Completed
NCT01618968Antares TherapeuticsMTX

Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device

Start: May 2012Est. completion: Aug 2012
Phase 2Completed
NCT01618955Antares TherapeuticsVIBEX MTX

Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device

Start: May 2012Est. completion: Jul 2012
Phase 2Completed
NCT07245992PhilogenF8IL10

A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis

Start: Jan 2026Est. completion: Sep 202942 patients
Phase 1Recruiting
NCT05337345Bristol Myers SquibbSubcutaneous

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Start: May 2022Est. completion: Dec 2022104 patients
Phase 1Completed
NCT02105129HutchmedHMPL-523

A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523

Start: May 2014Est. completion: Dec 2015118 patients
Phase 1Completed
NCT02775656UCB PharmaUCB Cimzia Pregnancy Follow-up Study

UCB Cimzia Pregnancy Follow-up Study

Start: Nov 2016Est. completion: Dec 20171 patients
N/ATerminated
NCT02600455Bristol Myers SquibbSubcutaneous

Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Start: Sep 2013Est. completion: Jun 2016505 patients
N/ACompleted

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 6,186 patients
15 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)